Pharmacokinetic modulation and compositions for modified FN3 polypeptides
First Claim
Patent Images
1. A polypeptide comprising a fibronectin type III tenth (10Fn3) domain of 80 to 150 amino acids, wherein the 10Fn3 domain binds to a target molecule with a KD of less than 100 nM and comprises an amino acid sequence at least 60% identical to SEQ ID NO:
- 5;
wherein the 10Fn3 domain further comprises a C-terminal tail having the sequence of EIDKPCQ (residues 97-103 of SEQ ID NO;
199), and wherein the cysteine residue of the C-terminal tail is conjugated to a moiety selected from the group consisting of;
a polyoxyalkylene moiety, a radioactive moiety, a chemotherapeutic agent, and a label.
5 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure relates to novel vascular endothelial growth factor receptor (VEGFR)-binding polypeptides and methods for using these polypeptides to inhibit biological activities mediated by vascular endothelial growth factors (VEGFs). The present disclosure also provides various improvements relating to single domain binding polypeptides.
-
Citations
15 Claims
-
1. A polypeptide comprising a fibronectin type III tenth (10Fn3) domain of 80 to 150 amino acids, wherein the 10Fn3 domain binds to a target molecule with a KD of less than 100 nM and comprises an amino acid sequence at least 60% identical to SEQ ID NO:
- 5;
wherein the 10Fn3 domain further comprises a C-terminal tail having the sequence of EIDKPCQ (residues 97-103 of SEQ ID NO;
199), and wherein the cysteine residue of the C-terminal tail is conjugated to a moiety selected from the group consisting of;
a polyoxyalkylene moiety, a radioactive moiety, a chemotherapeutic agent, and a label. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
- 5;
Specification